Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC0010 vs Pemetrexed/Cisplatin in Advanced NSCLC
NCT03058094Phase 3Withdrawn
- Sponsor
- ACEA Therapeutics
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abivertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ACEA Therapeutics. Primary endpoint: Progression-Free Survival at 24 months. Planned start Dec 2018; status: withdrawn.
02
Drugs
abivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03058094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058094.